4D Molecular Therapeutics, Inc. (FDMT)
|Net Income (ttm)||-52.26M|
|Trading Day||January 19|
|Day's Range||45.40 - 51.00|
|52-Week Range||36.20 - 51.00|
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Pi...
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Nasdaq:FDMT
EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
Gene therapy developer 4D Molecular Therapeutics increases deal size by 58% ahead of $158 million IPO
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-ba...
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
4D Molecular Therapeutics operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Ph... [Read more...]
|IPO Date |
Dec 11, 2020
|Stock Exchange |
|Ticker Symbol |
In 2019, FDMT's revenue was $6.99 million, a decrease of -50.56% compared to the previous year's $14.13 million. Losses were -$49.31 million, 416.2% more than in 2018.
The average 12-month stock price forecast for FDMT is 44.00, which is a decrease of -10.17% from the latest price.